282 related articles for article (PubMed ID: 15328193)
1. Expression of thyrotropin-releasing hormone by human melanoma and nevi.
Ellerhorst JA; Naderi AA; Johnson MK; Pelletier P; Prieto VG; Diwan AH; Johnson MM; Gunn DC; Yekell S; Grimm EA
Clin Cancer Res; 2004 Aug; 10(16):5531-6. PubMed ID: 15328193
[TBL] [Abstract][Full Text] [Related]
2. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
3. Human melanoma cells express functional receptors for thyroid-stimulating hormone.
Ellerhorst JA; Sendi-Naderi A; Johnson MK; Cooke CP; Dang SM; Diwan AH
Endocr Relat Cancer; 2006 Dec; 13(4):1269-77. PubMed ID: 17158770
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi.
Gerami P; Wass A; Mafee M; Fang Y; Pulitzer MP; Busam KJ
Am J Surg Pathol; 2009 Dec; 33(12):1783-8. PubMed ID: 19809275
[TBL] [Abstract][Full Text] [Related]
5. Loss of EphB6 expression in metastatic melanoma.
Hafner C; Bataille F; Meyer S; Becker B; Roesch A; Landthaler M; Vogt T
Int J Oncol; 2003 Dec; 23(6):1553-9. PubMed ID: 14612926
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes.
Bordoni R; Fine R; Murray D; Richmond A
J Cell Biochem; 1990 Dec; 44(4):207-19. PubMed ID: 2095366
[TBL] [Abstract][Full Text] [Related]
7. Tumor progression in the human melanocytic system.
Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.
Bianchini F; Massi D; Marconi C; Franchi A; Baroni G; Santucci M; Mannini A; Mugnai G; Calorini L
Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):320-8. PubMed ID: 17499752
[TBL] [Abstract][Full Text] [Related]
9. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
Giehl KA; Nägele U; Volkenandt M; Berking C
J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of p53 is a late event in the development of malignant melanoma.
Lassam NJ; From L; Kahn HJ
Cancer Res; 1993 May; 53(10 Suppl):2235-8. PubMed ID: 8485708
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
12. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
13. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
14. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma.
Ding Y; Prieto VG; Zhang PS; Rosenthal S; Smith KJ; Skelton HG; Diwan AH
Cancer; 2006 Mar; 106(5):1123-9. PubMed ID: 16456815
[TBL] [Abstract][Full Text] [Related]
15. Analysis of APAF-1 expression in human cutaneous melanoma progression.
Baldi A; Santini D; Russo P; CatricalĂ C; Amantea A; Picardo M; Tatangelo F; Botti G; Dragonetti E; Murace R; Tonini G; Natali PG; Baldi F; Paggi MG
Exp Dermatol; 2004 Feb; 13(2):93-7. PubMed ID: 15009102
[TBL] [Abstract][Full Text] [Related]
16. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance.
Nambiar S; Mirmohammadsadegh A; Hassan M; Mota R; Marini A; Alaoui A; Tannapfel A; Hegemann JH; Hengge UR
Carcinogenesis; 2007 Dec; 28(12):2501-10. PubMed ID: 17768177
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of telomerase activity in cutaneous melanocytic proliferations.
Miracco C; Pacenti L; Santopietro R; Laurini L; Biagioli M; Luzi P
Hum Pathol; 2000 Sep; 31(9):1018-21. PubMed ID: 11014565
[TBL] [Abstract][Full Text] [Related]
18. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
19. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
20. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma.
Banky JP; Kelly JW; English DR; Yeatman JM; Dowling JP
Arch Dermatol; 2005 Aug; 141(8):998-1006. PubMed ID: 16103329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]